NADAC acquisition cost data for REBIF 22 MCG/0.5 ML SYRINGE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 44087002203 | $1,400.93 | 2021-01-15 | Rx |
| 44087002203 | $1,400.93 | 2021-01-15 | Rx |
Generic: Interferon Beta-1a/Albumin | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $242.1M | 29,000 | 3,243 | $1,318.63 |
| 2020 | $232.7M | 25,470 | 2,795 | $1,415.55 |
| 2021 | $198.7M | 20,587 | 2,311 | $1,530.74 |
| 2022 | $162.3M | 16,085 | 1,815 | $1,608.45 |
| 2023 | $131.3M | 11,998 | 1,364 | $1,732.74 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $10.8M | 955 | 106 |
| Florida | $8.6M | 793 | 97 |
| Michigan | $7.8M | 732 | 95 |
| California | $7.2M | 616 | 77 |
| Illinois | $6.9M | 624 | 73 |
| Pennsylvania | $6.4M | 607 | 69 |
| Texas | $5.9M | 570 | 70 |
| Ohio | $5.5M | 543 | 58 |
| Indiana | $5.1M | 511 | 52 |
| Georgia | $4.7M | 418 | 50 |
| North Carolina | $4.0M | 361 | 42 |
| Minnesota | $4.0M | 358 | 46 |
| New Jersey | $3.9M | 319 | 39 |
| Missouri | $3.7M | 323 | 35 |
| Colorado | $3.5M | 310 | 32 |
| Tennessee | $3.1M | 280 | 31 |
| Massachusetts | $2.9M | 281 | 31 |
| Virginia | $2.7M | 243 | 26 |
| Washington | $2.6M | 234 | 27 |
| South Carolina | $2.6M | 226 | 29 |
| Arizona | $2.3M | 202 | 25 |
| Alabama | $2.2M | 204 | 22 |
| Wisconsin | $1.9M | 183 | 25 |
| Maine | $1.6M | 167 | 17 |
| Kentucky | $1.5M | 166 | 18 |
| Maryland | $1.4M | 125 | 15 |
| Kansas | $1.4M | 125 | 16 |
| North Dakota | $1.3M | 130 | 14 |
| Nevada | $1.2M | 119 | 14 |
| Mississippi | $1.1M | 82 | 12 |
| Louisiana | $1.1M | 99 | 12 |
| Iowa | $1.1M | 102 | 13 |
| Oregon | $1.0M | 92 | 12 |
| West Virginia | $979.0K | 93 | N/A |
| Utah | $971.5K | 77 | 12 |
| Connecticut | $970.8K | 70 | 11 |
| Nebraska | $860.5K | 75 | N/A |
| New Mexico | $752.8K | 76 | N/A |
| Puerto Rico | $747.3K | 76 | N/A |
| South Dakota | $746.4K | 62 | N/A |
| Arkansas | $715.2K | 67 | N/A |
| Idaho | $496.1K | 42 | N/A |
| Oklahoma | $463.4K | 45 | N/A |
| New Hampshire | $445.9K | 39 | N/A |
| District of Columbia | $366.3K | 27 | N/A |
| Delaware | $295.4K | 19 | N/A |
| Alaska | $288.7K | 27 | N/A |
| Rhode Island | $277.0K | 26 | N/A |
| Montana | $271.8K | 25 | N/A |
| Wyoming | $269.5K | 24 | N/A |
| Hawaii | $242.8K | 22 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.